Published in PLoS One on May 18, 2012
Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci (2012) 1.79
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis (2014) 1.14
Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. Am J Respir Crit Care Med (2015) 1.12
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
Systemic Inflammation in Older Adults With Asthma-COPD Overlap Syndrome. Allergy Asthma Immunol Res (2014) 1.10
Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res (2012) 1.07
Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res (2013) 1.06
Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum. PLoS One (2012) 1.02
Compartment differences of inflammatory activity in chronic obstructive pulmonary disease. Respir Res (2014) 0.98
Daily step count predicts acute exacerbations in a US cohort with COPD. PLoS One (2013) 0.98
Synergy-COPD: a systems approach for understanding and managing chronic diseases. J Transl Med (2014) 0.94
Influence of diet and obesity on COPD development and outcomes. Int J Chron Obstruct Pulmon Dis (2014) 0.93
Systemic inflammatory response to smoking in chronic obstructive pulmonary disease: evidence of a gender effect. PLoS One (2014) 0.93
Serum cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.92
Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. AIDS (2014) 0.91
Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study. PLoS One (2014) 0.88
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med (2014) 0.88
COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol (2015) 0.87
Inflammatory Markers and the Risk of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.87
Interleukin-6 and interleukin-8 blood levels' poor association with the severity and clinical profile of ex-smokers with COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.86
Lung Malignancies in HIV Infection. Semin Respir Crit Care Med (2016) 0.85
Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol (2014) 0.84
Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling. COPD (2013) 0.84
Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. ScientificWorldJournal (2014) 0.84
COgnitive-pulmonary disease. Biomed Res Int (2014) 0.84
Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review. PLoS One (2015) 0.83
Future directions: lung aging, inflammation, and human immunodeficiency virus. Clin Chest Med (2013) 0.83
Increased serum ox-LDL levels correlated with lung function, inflammation, and oxidative stress in COPD. Mediators Inflamm (2013) 0.82
Relation between systemic inflammatory markers, peripheral muscle mass, and strength in limb muscles in stable COPD patients. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Neutrophil-to-lymphocyte ratio, calprotectin and YKL-40 in patients with chronic obstructive pulmonary disease: correlations and 5-year mortality - a cohort study. J Inflamm (Lond) (2015) 0.82
The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD). PLoS One (2013) 0.81
Mobile-phone-based home exercise training program decreases systemic inflammation in COPD: a pilot study. BMC Pulm Med (2014) 0.81
Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) (2014) 0.81
Role of Serum Interleukin 6, Albumin and C-Reactive Protein in COPD Patients. Tanaffos (2015) 0.81
Fracture prevention in COPD patients; a clinical 5-step approach. Respir Res (2015) 0.80
Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med (2013) 0.80
Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings. J Thorac Dis (2015) 0.80
Biomarkers in chronic obstructive pulmonary disease: confusing or useful? Int J Chron Obstruct Pulmon Dis (2014) 0.80
The concept of control of COPD in clinical practice. Int J Chron Obstruct Pulmon Dis (2014) 0.80
A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Syst Biol (2014) 0.80
Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis (2016) 0.80
The effect of PPE-induced emphysema and chronic LPS-induced pulmonary inflammation on atherosclerosis development in APOE*3-LEIDEN mice. PLoS One (2013) 0.79
Obese COPD is associated with higher systemic inflammation - A new COPD phenotype. Lung India (2016) 0.79
Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. PLoS One (2015) 0.79
The systemic inflammome of severe obesity before and after bariatric surgery. PLoS One (2014) 0.79
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res (2014) 0.79
Strategies for Management of the Early Chronic Obstructive Lung Disease. Tuberc Respir Dis (Seoul) (2016) 0.78
Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons. AIDS (2016) 0.78
Phenotypic and genetic heterogeneity among subjects with mild airflow obstruction in COPDGene. Respir Med (2014) 0.78
Association between serum interleukin-6 concentrations and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PeerJ (2015) 0.78
Correlation of circulating MMP-9 with white blood cell count in humans: effect of smoking. PLoS One (2013) 0.78
Preserved function and reduced angiogenesis potential of the quadriceps in patients with mild COPD. Respir Res (2014) 0.78
A simple clinical measure of quadriceps muscle strength identifies responders to pulmonary rehabilitation. Pulm Med (2014) 0.78
Imbalance of dendritic cell co-stimulation in COPD. Respir Res (2015) 0.78
Utility of the combination of serum highly-sensitive C-reactive protein level at discharge and a risk index in predicting readmission for acute exacerbation of COPD. J Bras Pneumol (2014) 0.77
CD11b immunophenotyping identifies inflammatory profiles in the mouse and human lungs. Mucosal Immunol (2015) 0.77
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genet (2016) 0.77
COPD disease severity and innate immune response to pathogen-associated molecular patterns. Int J Chron Obstruct Pulmon Dis (2016) 0.77
Plasma Chemokine signature correlates with lung goblet cell hyperplasia in smokers with and without chronic obstructive pulmonary disease. BMC Pulm Med (2015) 0.77
Chronic obstructive pulmonary disease phenotype desaturator with hypoxic vascular remodelling and pulmonary hypertension obtained by cluster analysis. Multidiscip Respir Med (2012) 0.77
Health effects of the Federal Bureau of Prisons tobacco ban. BMC Pulm Med (2012) 0.77
Interleukin-6 and statin therapy: potential role in the management of COPD. Respir Res (2013) 0.77
Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.77
Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomark Insights (2016) 0.76
Association of the Neutrophil-to-Lymphocyte Ratio with Lung Function and Exacerbations in Patients with Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.76
Muscular Dysfunction in COPD: Systemic Effect or Deconditioning? Lung (2016) 0.76
Comorbidity and Inflammatory Markers May Contribute to Predict Mortality of High-Risk Patients With Chronic Obstructive Pulmonary Disease Exacerbation. J Clin Med Res (2016) 0.76
Home-based pulmonary rehabilitation improves clinical features and systemic inflammation in chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis (2015) 0.76
Inflammatory markers and mortality among US adults with obstructive lung function. Respirology (2015) 0.75
Frailty in Pulmonary and Critical Care Medicine. Ann Am Thorac Soc (2016) 0.75
Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification. Pak J Med Sci (2017) 0.75
Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Probing Cellular and Molecular Mechanisms of Cigarette Smoke-Induced Immune Response in the Progression of Chronic Obstructive Pulmonary Disease Using Multiscale Network Modeling. PLoS One (2016) 0.75
Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study. PLoS One (2016) 0.75
Constant-load exercise decreases the serum concentration of myeloperoxidase in healthy smokers and smokers with COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Lung cancer in persons with HIV. Curr Opin HIV AIDS (2017) 0.75
Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease. Mediators Inflamm (2016) 0.75
Comparison of biomarkers in serum and induced sputum of patients with occupational asthma and chronic obstructive pulmonary disease. J Occup Health (2016) 0.75
Airway gene expression of IL-1 pathway mediators predicts exacerbation risk in obstructive airway disease. Int J Chron Obstruct Pulmon Dis (2017) 0.75
A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease. J Am Med Dir Assoc (2016) 0.75
SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD. Sci Rep (2017) 0.75
Serum Vitamin A and Inflammatory Markers in Individuals with and without Chronic Obstructive Pulmonary Disease. Mediators Inflamm (2015) 0.75
Symptom profiles and inflammatory markers in moderate to severe COPD. BMC Pulm Med (2016) 0.75
Evaluation of plasma leptin, tumor necrosis factor-α, and prealbumin as prognostic biomarkers during clinical recovery from acute exacerbations of chronic obstructive pulmonary disease. Lung India (2017) 0.75
Advances in understanding COPD. F1000Res (2016) 0.75
Specific networks of plasma acute phase reactants are associated with the severity of chronic obstructive pulmonary disease: a case-control study. Int J Med Sci (2017) 0.75
Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication. Ther Clin Risk Manag (2013) 0.75
Study design for a randomised controlled trial to explore the modality and mechanism of Tai Chi in the pulmonary rehabilitation of chronic obstructive pulmonary disease. BMJ Open (2016) 0.75
Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD. BMC Pulm Med (2014) 0.75
COPD: it is time to change! Int J Chron Obstruct Pulmon Dis (2015) 0.75
Lung Disease and Hypertension. Pulse (Basel) (2015) 0.75
Systemic IL-6 Effector Response in Mediating Systemic Bone Loss Following Inhalation of Organic Dust. J Interferon Cytokine Res (2016) 0.75
Natural course of early COPD. Int J Chron Obstruct Pulmon Dis (2017) 0.75
The prognostic value of measurement of high-sensitive cardiac troponin T for mortality in a cohort of stable chronic obstructive pulmonary disease patients. BMC Pulm Med (2016) 0.75
Risk factors for FEV1 decline in mild COPD and high-risk populations. Int J Chron Obstruct Pulmon Dis (2017) 0.75
The RESPECT study: RESearch on the PrEvalence and the diagnosis of COPD and its Tobacco-related etiology: a study protocol. BMC Public Health (2015) 0.75
Heterogeneity of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Network medicine: a network-based approach to human disease. Nat Rev Genet (2011) 14.07
A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60
Points of control in inflammation. Nature (2002) 10.61
International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (2007) 10.12
Global burden of COPD: risk factors, prevalence, and future trends. Lancet (2007) 9.50
Mechanisms linking obesity with cardiovascular disease. Nature (2006) 9.07
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax (2004) 8.09
The global burden of disease, 1990-2020. Nat Med (1998) 6.50
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
From COPD to chronic systemic inflammatory syndrome? Lancet (2007) 4.13
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.85
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69
Systemic effects of chronic obstructive pulmonary disease. Eur Respir J (2003) 3.44
Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax (2010) 3.06
Systemic inflammation and COPD: the Framingham Heart Study. Chest (2007) 2.74
Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett (2005) 2.30
Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med (2010) 2.09
Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol (2006) 1.79
Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res (2010) 1.79
Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.79
Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Med (2011) 1.78
Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 1.78
Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? Eur Respir J (2008) 1.76
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc (2007) 1.45
Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med (2010) 1.23
Systemic effects in COPD. Chest (2002) 1.19
An integrative systems biology approach to understanding pulmonary diseases. Chest (2010) 1.18
C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax (2010) 1.07
Facing a "slow-motion disaster"--the UN meeting on noncommunicable diseases. N Engl J Med (2011) 1.00
The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis (2009) 0.98
New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc (2009) 0.97
Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc (2006) 0.88
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med (2004) 17.08
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med (2007) 8.06
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 7.67
Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65
Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92
Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75
Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation (2005) 4.71
PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med (2011) 4.16
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96
Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93
An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91
A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78
Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J (2004) 3.77
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69
Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ (2011) 3.61
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58
A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52
Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44